<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04031287</url>
  </required_header>
  <id_info>
    <org_study_id>MLD_CT1.0</org_study_id>
    <nct_id>NCT04031287</nct_id>
  </id_info>
  <brief_title>RCDP Natural History Study</brief_title>
  <official_title>A Prospective Natural History Study of Patients With Rhizomelic Chondrodysplasia Punctata (RCDP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MED-LIFE DISCOVERIES LP</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MED-LIFE DISCOVERIES LP</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, longitudinal observational trial in patients with RCDP. Study participants
      will be evaluated at baseline and approximately every 6 months by the study team. Quality of
      life, physiologic and functional measurements will be performed. In addition, audiologic
      recordings and other surveys will be completed at home by parents beginning at baseline and
      every 3-6 months thereafter.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rhizomelic chondrodysplasia punctata (RCDP) is a group of rare diseases that have no known
      cure. It is a genetic disorder characterized by mutations in the Peroxisomal Biogenesis
      Factor 7 (PEX7) gene (RCDP1), Glyceronephosphate O-acyltransferase (GNPAT) gene (RCDP 2),
      Alkylglycerone phosphate synthase (AGPS) gene (RCDP3), Fatty Acyl-CoA Reductase 1 (FAR1) gene
      (RCDP4) or Peroxisomal Biogenesis Factor 7 (PEX7) gene (RCDP5) all coding for peroxisomal
      proteins which result in defective synthesis of plasmalogens. Hence, severely decreased
      levels of ethanolamine plasmalogens (PlsEtn), the most common tissue plasmalogen, is both the
      biochemical hallmark and the primary cause of pathology for all RCDP groups. To treat RCDP, a
      plasmalogen replacement is under development. Before this therapeutic or any therapeutic for
      RCDP can be tested for efficacy in the clinic, a thorough understanding of the natural
      progression of the disease is required. Without this information it would be impossible to
      determine whether the drug was effectively improving the disease course. Classical, or
      severe, is the most common form of RCDP and presents in the neonatal period. It is clinically
      characterized by a skeletal dysplasia as seen by symmetrical rhizomelic shortening of the
      long bones. Chondrodysplasia is also present with premature calcification of epiphyseal
      cartilage (punctata), delayed calcification of vertebral bodies and mineralization of
      cartilaginous structures which do not normally ossify, such as the larynx, trachea and
      intervertebral discs. Additionally patients display dysmorphic facial features, bilateral
      cataracts, cognitive deficits and severe growth and psychomotor delays. Shortened life
      expectancy is common to RCDP patients; however survival varies widely. For the classical
      form, of those individuals who survive the first month of life, 50% will survive until 6
      years of age with nearly all succumbing to the disease by adolescence. The majority of deaths
      are secondary to respiratory problems5. The chronic respiratory compromise is due to the
      skeletal defects, as well as the direct effect of plasmalogen deficiency on lung cellular
      function. Patients with less severe phenotypes can lack rhizomelia, and have less severe
      growth and developmental delays. The disease phenotype varies considerably and correlates
      directly with PlsEtn abundance.

      STUDY RATIONALE Determining the appropriate measurable endpoints are as important as having a
      viable therapeutic strategy for a clinical trial. In a disease like RCDP, endpoints must be
      sensitive enough to measure subtle changes in the course of the disease and also be
      meaningful to the process of pathogenesis. Assessment of a RCDP treatment trial is a complex
      task as RCDP clinical trajectory might be influenced by the disease severity, age and care
      that the patient receives etc. Moreover, although measurement scales exist for such diseases
      as Cerebral Palsy to assess the severity of the disease, RCDP does not have such universally
      accepted overall set of measures that assess patient's developmental, functional,
      psychosocial, neurological, skeletal, and respiratory functions as a whole. Lack of such
      grading scales is a hindrance to evaluate the progress of a clinical trial in a complex and
      severe disease as RCDP. In a disease like RCDP, more than a complete cure, a functional
      improvement in patient's life could be considered as efficacious.

      The other issue in a rare disease clinical trial design is the comparator to which the effect
      of treatment can be compared. Ethical considerations preclude having a placebo control and a
      more appropriate comparator is a non-concurrent control group. Therefore, longitudinal
      assessments are required to determine the inherent variability in functional measures and
      characterize the disease trajectory. To this end, we have designed an on-going longitudinal
      observational trial with assessments every 3-6 months to characterize RCDP and its disease
      course.

      Overarching goal is to determine the longitudinal and natural trajectory of disease state in
      patients with RCDP by assess the quality of life, physiologic and functional measures.

      Specific measurements will include:

        -  Medical and surgical history

        -  Anthropometric measurements

        -  Vital signs

        -  Physical examination

        -  Observational pain assessment

        -  Musculoskeletal system assessment

        -  Nerve conduction studies

        -  Non-invasive pulmonary function tests

             -  Impulse Oscillometry System

             -  Pneumotachography

             -  Respiratory Inductance Plethysmography

        -  4 hour EEG

        -  DEXA

        -  Questionnaire assessment of:

             -  Iowa Fatigue Scale

             -  Pediatric Pain Scale

             -  NCCPC-R (Pain Scale)

             -  Infant Gastrointestinal Symptom Questionnaire

             -  Pediatric Assessment Scale for Severe Feeding Problems

        -  LENA

        -  Parental written logs (over 2 days)

             -  Activity

             -  Pain

             -  Seizure

        -  Blood Assessments

             -  Plasmalogen and Lipids

             -  Complete Blood Count

             -  Comprehensive Metabolic Panel

             -  Genetic Testing (if not available from history)

      STUDY DESIGN

      As described above, clinical characteristics of RCDP encompass a wide range of signs,
      symptoms, physiological, functional and structural abnormalities all of which must be taken
      in to account when assessing a patient's progress. The major systems affected are the
      skeletal system (severe and symmetrical shortening of proximal long bones, stippled
      epiphyses, dysmorphia and contractures), neurophysiological (seizures), neuromuscular and
      psychomotor abnormalities, respiratory, growth and developmental and daily function. Many of
      these symptoms can be characterized by standard tests that are in clinical or research use.
      Other assessments, such as the quality of life, require the development of novel tools which
      will be implemented once they have been validated. Assessing each domain in its own right
      will provide the best indication of efficacy on an individual basis.

      Domain specific milestones as described here will increase the sensitivity in assessing
      treatment specific effects. Acute clinically evident improvements brought about by
      plasmalogen replacement therapy are expected to be subtle. The earliest improvements are
      anticipated to be improvements in membrane-related functions such as improved
      neurotransmission, improved neuromuscular function, improved GI function, increase growth
      rates and better lung health. Functionally, we anticipate that primary and immediate
      improvements will be evident in motor function, frequency of seizures, frequency of pulmonary
      infections and improved quality of life. Improvements in other systems and function are
      anticipated to arise later in a gradual manner. Consequently, assessment of each of these
      domains as well as an assessment of quality of life and measures of functionality are needed
      to estimate therapeutic benefits accurately.

      The study is intended to be on-going, allowing for longitudinal assessment of RCDP. In-
      hospital assessments will be completed approximately every 6 months, based on availability of
      scheduling and patients' health. In home audiologic recordings will take place after each
      study visit along with parent completed logs. In home surveys will be distributed every 3
      months to the caregiver.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 18, 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>18 Months</target_duration>
  <primary_outcome>
    <measure>Medical History</measure>
    <time_frame>18 months</time_frame>
    <description>History collection will be obtained from parents/caretakers and medical records which will be provided or subsequently obtained in a HIPAA compliant manner.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body Temperature</measure>
    <time_frame>18 months</time_frame>
    <description>Temperature will be recorded using standard clinical methodology and reported in degrees Celsius.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Respiratory Rate</measure>
    <time_frame>18 months</time_frame>
    <description>Respiratory rate will be determined by counting number of breaths per minute</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>18 months</time_frame>
    <description>Heart rate will be reported as beats per minute</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>18 months</time_frame>
    <description>Systolic and diastolic pressure will be reported in mmHG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical Examination: General Appearance</measure>
    <time_frame>18 months</time_frame>
    <description>Reported as &quot;Normal, Abnormal or Not Done&quot;. If abnormal, comments will be provided.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical Examination: Head, Eyes, Ears, Nose and Throat</measure>
    <time_frame>18 months</time_frame>
    <description>Reported as &quot;Normal, Abnormal or Not Done&quot;. If abnormal, comments will be provided.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical Examination: Cardiovascular</measure>
    <time_frame>18 months</time_frame>
    <description>Reported as &quot;Normal, Abnormal or Not Done&quot;. If abnormal, comments will be provided.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical Examination: Dermatologic</measure>
    <time_frame>18 months</time_frame>
    <description>Reported as &quot;Normal, Abnormal or Not Done&quot;. If abnormal, comments will be provided.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical Examination: Lymphatic</measure>
    <time_frame>18 months</time_frame>
    <description>Reported as &quot;Normal, Abnormal or Not Done&quot;. If abnormal, comments will be provided.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical Examination: Respiratory</measure>
    <time_frame>18 months</time_frame>
    <description>Reported as &quot;Normal, Abnormal or Not Done&quot;. If abnormal, comments will be provided.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical Examination: Gastrointestinal</measure>
    <time_frame>18 months</time_frame>
    <description>Reported as &quot;Normal, Abnormal or Not Done&quot;. If abnormal, comments will be provided.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical Examination: Genitourinary</measure>
    <time_frame>18 months</time_frame>
    <description>Reported as &quot;Normal, Abnormal or Not Done&quot;. If abnormal, comments will be provided.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical Examination: Neurologic System</measure>
    <time_frame>18 months</time_frame>
    <description>Reported as &quot;Normal, Abnormal or Not Done&quot;. If abnormal, comments will be provided.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical Examination: FLACC Behavioural Scale</measure>
    <time_frame>18 months</time_frame>
    <description>The standardized FLACC (Faces, Legs, Activity, Consolability) questionnaire will be performed and the score reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anthropometric Measurement: Length/Height</measure>
    <time_frame>18 months</time_frame>
    <description>Height (Length) will be reported in centimetres</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anthropometric Measurement: Weight</measure>
    <time_frame>18 months</time_frame>
    <description>Weight will be reported in kg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anthropometric Measurement: Head Circumference</measure>
    <time_frame>18 months</time_frame>
    <description>Head Circumference will be reported in cm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anthropometric Measurement: Chest Circumference</measure>
    <time_frame>18 months</time_frame>
    <description>Chest Circumference will be reported in cm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anthropometric Measurement: Abdominal Circumference</measure>
    <time_frame>18 months</time_frame>
    <description>Abdominal Circumference will be reported in cm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observational pain assessment</measure>
    <time_frame>18 months</time_frame>
    <description>Frequency and severity of patient exhibited pain symptoms will be evaluated with two parent-completed questionnaires, The Non-Communicating Children's Pain Checklist- Revised (NCCPC-R) and the Pediatric Pain Scale (PPS)19 (Appendix G). The NCCPC-R is a 7 domain questionnaire that is validated for assessment of pain in children aged 3-18 years who have cognitive and communication impairments. The PPS has 20 domains with a rating scale for each which is also designed to assess symptoms of pain in individuals with communication impairment. Both questionnaires will be completed during the study visits 2 hours after the end of the first morning feed. In addition, the NCCPC-R will be completed by the family 3 months after each visit at the same time interval after the first morning feed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Musculoskeletal system assessment</measure>
    <time_frame>18 months</time_frame>
    <description>Musculoskeletal evaluations will be done together by a physiatrist and physical therapy. These assessments will include: assessments of strength, endurance, functional movement and control of extremities, head/neck and trunk. Assessment of muscle tone and passive and active joint range of motion will be made both qualitative and quantitatively for each major joint. Assessment of cognitive engagement will also be made. To assess the motor function and its changes over time, we propose to use Gross Motor Function Measures (GMFM-88), which is a freely available tool validated to evaluate motor skills in cerebral palsy and Down syndrome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nerve conduction</measure>
    <time_frame>18 months</time_frame>
    <description>Patients will be placed in a supine position and electrodes will be placed over the hypothenar eminence, 5th digit and dorsal hand. Stimulations will be done at the wrist and above and below the elbow. These electrodes will be connected to the Natus UltraPro S100 machine. This unit will measure nerve conduction for motor and sensory components. The evaluation will assess nerve latencies, compound motor unit and sensory nerve action potential amplitudes and nerve conduction velocities. These values will be compared to age adjusted normal values for the ulnar nerve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary function</measure>
    <time_frame>18 months</time_frame>
    <description>A combination of Impulse oscillometry system (IOS), Pneumotachography (PNT) and Respiratory Inductance Plethysmography (RIP) will be used to derive pulmonary indices comparable to spirometry.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seizure status by EEG</measure>
    <time_frame>18 months</time_frame>
    <description>Assessments of brain electrical and seizure activity will take place through electroencephalograms (EEGs) at each study visit. Each EEG will last 4 hours and will be scheduled to optimally include both awake and sleep phases. Using the 10-20 International System, the patient's head will be measured and marked for proper electrode placement. Heart rate and rhythm are monitored throughout the EEG by placement of two electrocardiogram electrodes. Electrical activity is then recorded along with a video feed using the Nicolet NicOne acquisition and Xltek brain monitor machines.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Density and Body Composition by DEXA</measure>
    <time_frame>18 months</time_frame>
    <description>The DEXA scans will be performed in the Medical Imaging Department of Nemours/A.I. duPont Hospital for Children on a Hologic Discovery A QDR bone densitometer (Hologic, Inc., Bedford, MA). Subjects will remove all clothing with metal components prior to DEXA scan to eliminate any possible imaging artifacts; a hospital gown will be provided to the subjects. Standard positioning techniques will be used to acquire the scans. Body sites measured will include the whole body, lumbar spine, and lateral distal femurs of both legs. The following variables will be collected from each scan: bone mineral density (BMD), bone mineral content (BMC), and bone area.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasmalogen Level</measure>
    <time_frame>18 months</time_frame>
    <description>A 100 ul aliquot of the separated serum will be stored at -80 Â°C and subsequently shipped to Med-Life Discoveries by priority overnight shipment in dry ice. Analyses will include levels of phosphoethanolamines, vinylacylglycerol (VAG), alkylacylglycerol (AAG) and results reported as quantitative concentrations for each metabolite.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Chemistry</measure>
    <time_frame>18 months</time_frame>
    <description>Serum will be processed locally for complete blood count (CBC) and standard comprehensive metabolic profile with phosphorus (CMP with PO4).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fatigue status</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastrointestinal and Feeding status</measure>
    <time_frame>18 months</time_frame>
    <description>To assess level of dysfunction in swallowing, a parent report measure, the Pediatric Assessment Scale for Severe Feeding Problems, designed to assess progress in the development of oral eating skills for children who need prolonged tube feeding will be used. The total score will be used as a quantifiable measure. This questionnaire will be completed during each study visit as well as at home 3 months after each visit. This 13 question interview provides a total score which indicates the level of GI symptom burden.</description>
  </primary_outcome>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Rhizomelic Chondrodysplasia Punctata</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a diagnosis of RCDP are eligible.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of RCDP age range 6 months to 21 years

          -  A clinical diagnosis of RCDP confirmed with biochemical parameters defined as C16:0
             plasmalogen level of less than or equal to 0.75 of the lower limit of the normal
             reference range AND normal very long chain fatty acid levels.

        Exclusion Criteria:

          -  Disease severity: The study physician will decide whether the child is too ill to
             travel due to chronic or acute severe cardiac or respiratory compromise.

          -  Guardian or a care-giver who is not available or not capable of providing accurate
             information about the patient.

          -  Involvement in any other clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>21 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Michael Bober, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Nemours Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shawn Ritchie, PhD</last_name>
    <phone>306-244-8233</phone>
    <email>s.ritchie@med-life.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tara Smith, PhD</last_name>
    <phone>306-244-8233</phone>
    <email>t.smith@med-life.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alfred I. DuPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Candace Muss</last_name>
      <phone>302-651-5476</phone>
      <email>candace.muss@nemours.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 13, 2019</study_first_submitted>
  <study_first_submitted_qc>July 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2019</study_first_posted>
  <last_update_submitted>August 1, 2019</last_update_submitted>
  <last_update_submitted_qc>August 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chondrodysplasia Punctata, Rhizomelic</mesh_term>
    <mesh_term>Chondrodysplasia Punctata</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

